Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Neoadjuvant chemotherapy in patients with high-grade upper tract urothelial carcinoma

Wesley Yip, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the findings of a multicenter Phase II study evaluating gemcitabine and cisplatin as neoadjuvant chemotherapy in patients with high-grade upper tract urothelial carcinoma (UTUC). Neoadjuvant chemotherapy for high-risk UTUC demonstrates outcomes of favorable pathologic response, is well tolerated requiring minimal delay to surgery without significant perioperative complication risk, and thus should be considered a new standard of care option for patients with high-risk UTUC. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.